The Food and Drug Administration (FDA) has approved a new administration option for Brilinta (ticagrelor; AstraZeneca) for patients who are unable to swallow the 90mg tablets whole.

Brilinta tablets are now approved to be crushed and administered in water by swallowing or via nasogastric tube. The updated prescribing information states that the crushed tablets should be mixed with water and drunk immediately. The mixture can also be administered via nasogastric tube (CH8 or greater).

RELATED: Da Hee Han, PharmDMarch 16, 2015Long-Term Study on Brilinta Safety, Efficacy Announced

Brilinta is a P2Y12 platelet inhibitor (cyclopentyltriazolopyrimidine) indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina or non-ST-elevation myocardial infarction [MI] or ST-elevation MI).

Brilinta is available as 90mg strength tablets in 14-, 60-, and 180-count bottles.

For more information call (800) 237-8898 or visit